{"id":610976,"date":"2026-08-31T09:21:34","date_gmt":"2026-08-31T09:21:34","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/610976\/ace-therapeutics-delivers-comprehensive-preclinical-pharmacokinetic-evaluation-services-to-support-novel-cardiovascular-therapeutic-development.html"},"modified":"2026-08-31T09:21:34","modified_gmt":"2026-08-31T09:21:34","slug":"ace-therapeutics-delivers-comprehensive-preclinical-pharmacokinetic-evaluation-services-to-support-novel-cardiovascular-therapeutic-development","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/610976\/ace-therapeutics-delivers-comprehensive-preclinical-pharmacokinetic-evaluation-services-to-support-novel-cardiovascular-therapeutic-development.html","title":{"rendered":"Ace Therapeutics Delivers Comprehensive Preclinical Pharmacokinetic Evaluation Services to Support Novel Cardiovascular Therapeutic Development"},"content":{"rendered":"
Ace Therapeutics has expanded its integrated preclinical study solutions for cardiovascular drug development, with a focus on pharmacokinetic evaluation to support early-stage candidate characterization.<\/div>\n

New York, NY, United States – August 31, 2026 –<\/strong> Ace Therapeutics, a contract research organization focused on cardiovascular drug research, offers integrated study solutions covering preclinical pharmacokinetic evaluation of cardiovascular drugs<\/a> to meet growing preclinical development demands for cardiovascular therapeutics.<\/p>\n

The pharmacokinetic profile of a cardiovascular drug candidate is an important determinant of systemic exposure and can influence dose selection, efficacy, and safety during development. For systemically administered cardiovascular therapies, achieving appropriate systemic exposure and duration of exposure is an important consideration in candidate optimization and dose selection. Cardiovascular drug PK studies generate critical data reflecting drug concentration changes across body tissues over time and quantify in vivo<\/em> pharmacokinetic characteristics, forming the scientific foundation for subsequent dosage\u2011form design and delivery\u2011system optimization.<\/p>\n

Ace Therapeutics provides both in vitro<\/em> ADME and in vivo cardiovascular drug PK studies<\/a> in the early\u2011development phase. Its in vitro<\/em> ADME evaluation service helps clients characterize metabolic profiles of cardiovascular candidates. Complementary in vivo<\/em> PK studies characterize systemic exposure and pharmacokinetic profiles using study designs tailored to the properties and development stage of individual candidates. The technical platform enables flexible, customized preclinical pharmacokinetic evaluation of cardiovascular drugs aligned with individual client research goals.<\/p>\n

Rigorous preclinical pharmacokinetic work reduces developmental risks for cardiovascular candidates by clarifying absorption, metabolism, distribution, and elimination characteristics before clinical translation.<\/p>\n

“Robust pharmacokinetic characterization is indispensable for moving promising cardiovascular drug candidates forward,” commented a senior scientist at Ace Therapeutics. “Our cardiovascular drug PK studies aim to produce actionable preclinical evidence, helping R&D teams make informed decisions for candidate progression.”<\/p>\n

In addition to cardiovascular PK studies, Ace Therapeutics supports related preclinical programs in pharmacodynamic assessment and toxicology. Organizations interested in accessing these service offerings can contact Ace Therapeutics for further project consultation.<\/p>\n

About Ace Therapeutics<\/strong><\/p>\n

Ace Therapeutics is a specialized contract research organization supporting cardiovascular drug discovery and development. Equipped with dedicated pharmacokinetic research infrastructure, Ace Therapeutics can deliver custom\u2011fit preclinical research services for global biotech and pharmaceutical partners working on cardiovascular drug discovery and development.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Ace Therapeutics<\/a>
Contact Person:<\/strong> Daisy Mostert
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1 516 441 0167
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.acetherapeutics.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Ace Therapeutics has expanded its integrated preclinical study solutions for cardiovascular drug development, with a focus on pharmacokinetic evaluation to support early-stage candidate characterization. New York, NY, United States –<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/610976"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=610976"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/610976\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=610976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=610976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=610976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}